By assessing pathological and immunhistochemical variables in this rare tumor entity, as well as the clinical courses of patients treated within different treatment schedules including immunotherapy and anti-VEGF-therapy, we aimed to show similarities to cervical cancer where emerging therapeutic options have improved survival significantly. The gene discussed is VEGFA; the disease is cervical cancer.